GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » 5-Year Yield-on-Cost %

VIA Pharmaceuticals (VIA Pharmaceuticals) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 21, 2024)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals 5-Year Yield-on-Cost %?

VIA Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2010 was 0.00.


The historical rank and industry rank for VIA Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



VIAP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.89
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of VIA Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, VIA Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIA Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIA Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where VIA Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



VIA Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of VIA Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

VIA Pharmaceuticals  (GREY:VIAP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


VIA Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus